Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gsk Consumer Healthcare Sarl has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, showing a distributed prosecution profile across separate technical assignments.
MEYERS, ELIZABETH ANNE is the busiest examiner, with 1 pending matter. The available data does not indicate examiner concentration. Counsel should manage each action independently, while preserving consistent positions on the relevant healthcare, pharmaceutical, and biotechnology terminology throughout the active portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
| MEYERS, ELIZABETH ANNE | 1 | 21.1% | +93.8% |
| LAU, JONATHAN S | 1 | 63.8% | -17.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570393 | NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC | SANCHEZ, JUSTIN CHRISTOPHER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570372 | MICELLAR SOLUTION COMPRISING DICLOFENAC | MEYERS, ELIZABETH ANNE | 58d overdue |
| 18002666 | ANTIVIRAL PHARMACEUTICAL COMPOSITION | LAU, JONATHAN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570372 | MICELLAR SOLUTION COMPRISING DICLOFENAC | MEYERS, ELIZABETH ANNE | 58d overdue |
| 18570393 | NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC | SANCHEZ, JUSTIN CHRISTOPHER | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1617 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570393 | NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18570372 | MICELLAR SOLUTION COMPRISING DICLOFENAC | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Final Rejection | 58d overdue | Pending | Dec 14, 2023 |
| 18002666 | ANTIVIRAL PHARMACEUTICAL COMPOSITION | LAU, JONATHAN S | 1693 | §102§103§112 | Non-Final OA | — | Pending | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGsk Consumer Healthcare Sarl has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Justin Christopher Sanchez has the most, with 1 of Gsk Consumer Healthcare Sarl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.